David Whellan, MD, Named Principal Investigator for SeaKing Solace SAIL Study Program
Following approximately eleven months of scientific discussion, program development, and diligence, SeaKing Solace and Thomas Jefferson University completed a statement of work defining the framework for the proposed Phase 1 SAIL study.
SeaKing Solace announced that David J. Whellan, MD, will serve as Principal Investigator for the proposed SAIL study program, marking an important institutional milestone in the development of the organization's Phase 1 research program. The appointment establishes a formal investigator leadership structure as SeaKing Solace advances from scientific hypothesis development toward detailed prospective study planning.
The milestone followed approximately eleven months of scientific discussions, protocol development, operational planning, diligence, and institutional review involving SeaKing Solace and Thomas Jefferson University. That process included development of a statement of work describing the proposed scientific and operational framework for Phase 1 and the anticipated responsibilities associated with continued study development.
Dr. Whellan is Deputy Provost for Research, Senior Associate Provost for Clinical Research, Associate Dean for Clinical Research at the Sidney Kimmel Medical College, and Executive Director of the Jefferson Clinical Research Institute at Thomas Jefferson University. His work in clinical trial design, research operations, and scientific oversight provides medical and methodological leadership for development of the proposed program. Additional information about his role is available on the SeaKing Solace Team page.
Defining the first prospective human research phase
SAIL is intended as the first prospective human research phase in the SeaKing Solace program. Its purpose is to characterize quantified natural multidimensional motion together with synchronized human physiological responses and determine whether reproducible stimulus-response relationships can be identified. It is a proposed discovery study, not a therapeutic trial.
The proposed scientific focus includes healthy adults, quantified vessel motion, participant-level or head-centered motion measurement, synchronized multimodal physiology, repeated exposure, tolerability, within-person reproducibility, and identification of candidate motion-response relationships. Measuring both the physical exposure and the participant's response is central to the architecture: without synchronized stimulus characterization, physiological observations cannot be interpreted with sufficient precision for later controlled reproduction.
Principal Investigator leadership matters because the research program requires integrated decisions about protocol design, participant safety, measurement quality, study conduct, analysis planning, and evidence interpretation. Dr. Whellan's role provides medical and scientific leadership for those development activities and establishes investigator oversight around the proposed study framework.
That leadership is especially important for a discovery program built around multiple synchronized data streams. Motion measurements, cardiovascular signals, autonomic measures, participant observations, and environmental context must be collected and interpreted within a coherent protocol. Decisions about timing, tolerability, repeat exposure, data quality, and analysis must be defined prospectively so that any apparent relationship can be evaluated without implying more than the study design supports.
The statement of work defines the proposed relationship between SeaKing Solace and Thomas Jefferson University and provides a framework for scientific responsibilities, study development, and operational planning associated with Phase 1. It is a research-program development milestone. It should not be interpreted as confirmation that the study has begun, that participants have been enrolled, that institutional review board approval has been granted, or that study funding is complete.
The milestone represents a transition from hypothesis development and literature review toward a defined prospective research program. The purpose of Phase 1 is not to demonstrate therapeutic efficacy, but to determine whether the underlying natural-motion hypothesis can be measured rigorously enough to justify subsequent controlled testing.
The same evidence-gated approach applies to the study's possible outcomes. Supportive findings would define questions for replication and controlled motion research rather than establish a clinical use. Mixed or heterogeneous findings could identify important sources of variation and refine later protocol design. Non-supportive results could narrow the hypothesis or indicate that a proposed path should not advance. Each outcome would inform the next scientific decision.
The proposed approach follows the evidence boundaries described in the SeaKing Solace scientific review series. A measurable physiological response would not, by itself, establish clinical benefit. Any candidate relationship would require replication, controlled reproduction, dose-response investigation, and later population-specific research before clinical conclusions could be considered.
SeaKing Solace will continue refining the research program, funding strategy, instrumentation, study operations, and institutional collaborations required before study execution. Future progress remains contingent on completing the scientific, operational, funding, ethics-review, and governance steps appropriate to prospective human research.
Continue exploring the SeaKing Solace research program.
Learn About the Research Program